A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer

Brief description of study

The purpose of the study is to assess effectiveness and safety of the intravesical BCG (Bacillus Calmetter-Guerin) in combination with ALT-803 in patients with BCG unresponsive high-grade non-muscle invasive bladder cancer (NMIBC). During the study, we want to know how the treatment affects your body and the growth of your tumor. You will receive a urinary catheter in the bladder, combined with the drugs. ALT-803 is an investigational drug, which means that it has not been approved by the U.S FDA, but the FDA has given its permission for ALT-803 to be tested in this research study.


Clinical Study Identifier: s18-00902
ClinicalTrials.gov Identifier: NCT03022825
Principal Investigators: iConnect Langone, Aaron Edward Katz.
Other Investigators: Anthony Corcoran, Jeffrey Todd Schiff, James R Lewis.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.